Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/15271
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.creatorPalacios Ceña, Domingo-
dc.creatorOrdás Bandera, Carlos-
dc.creatorCasas Limón, Javier-
dc.creatorPérez Corrales, Jorge-
dc.creatorGüeita Rodríguez, Javier-
dc.creatorArias Navalón, José Antonio-
dc.creatorCuadrado, María Luz-
dc.date.accessioned2024-02-01T13:46:39Z-
dc.date.available2024-02-01T13:46:39Z-
dc.date.issued2023-09-14-
dc.identifier.citationDomingo Palacios-Ceña, Carlos Ordás-Bandera, Javier Casas-Limón, Jorge Pérez-Corrales, Javier Güeita-Rodríguez, José A. Arias-Navalón & María-Luz Cuadrado (2023) Real-world experience of OnabotulinumtoxinA treatment in female patients with chronic migraine: a qualitative study using in-depth interviews, Annals of Medicine, 55:2, 2255215, DOI: 10.1080/07853890.2023.2255215en_EN
dc.identifier.issn1365-2060-
dc.identifier.urihttp://hdl.handle.net/10637/15271-
dc.description.abstractFive themes were identified: (a) A long way to go before Botox®, (b) First time hearing about the treatment and its expectations, (c) The administration of Botox®, (d) Treatment effects, and (e) Follow-up. Patients described a long history of treatment failures prior to the start of OBT-A treatment. Information about this migraine treatment came from the neurologist; following the information, patients had high expectations, including unrealistic expectations regarding the onset and duration of effect. They acknowledged fear of the injections and some discomfort due to the procedure. With treatment, participants reported better migraine control and an improvement in their quality of life. Follow-up had some barriers, such as delayed appointments for subsequent doses, but also strengths, such as effectiveness and few side effects. Conclusions: Qualitative research offers insight into how patients with CM experience treatment with OBT-A. Our results highlight some relevant aspects that should be considered when providing OBT-A treatment.en_EN
dc.language.isoen-
dc.publisherTaylor and Francis Group-
dc.relation.ispartofAnnals of Medicine-
dc.rightshttp://creativecommons.org/licenses/by/4.0/deed.es-
dc.rightsOpenAccess-
dc.subject(MeSH)en_EN
dc.subjectBotulinum toxin type Aen_EN
dc.subjectDrug therapyen_EN
dc.subjectMigraine disordersen_EN
dc.subjectWomenen_EN
dc.subjectQualitative researchen_EN
dc.titleReal-world experience of OnabotulinumtoxinA treatment in female patients with chronic migraine: a qualitative study using in-depth interviewsen_EN
dc.typeArtículoen_EN
dc.identifier.doi10.1080/07853890.2023.2255215-
dc.relation.projectIDThis study was supported by an independent research grant from the AbbVie Investigator-Initiated Studies program. AbbVie had no role in the study design, data collection or analysis.-
dc.centroUniversidad San Pablo-CEU-
Aparece en las colecciones: Medicina




Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.